Table 3.

SAGhE study: sources of GH treatment data

Country	Source of GH dataa	GH data collected prospectivelyb or retrospectivelyc
Belgium	National clinically run database	Prospectively
France	Yearly forms sent by clinical centres to a national agency until 1997; hospital case notes thereafter	Prospectively until 1997; thereafter retrospectively from hospital case notes in 3 sweeps (in 1999, 2001 and 2010)
Germany	National industry database, clinical non-industry database, plus local clinic case notes	Prospectively in industry and clinical databases; clinic notes retrospectively
Italy	GH treatment registries (Piedmont and Campania); local clinic case notes and National Institute of Health Registry	National registry prospectively; clinic notes retrospectively
The Netherlands	Paediatric endocrinologists, hospital records, clinical notes	Prospectively, with missing data added retrospectively
Sweden	National database independent of industry	Prospectively in national database
Switzerland	Original medical charts at centres of paediatric endocrinology, oncology, and nephrology	Retrospectively
UK	National industry database plus local clinic case notes for a minority	Prospectively in industry database; retrospectively for hospital case notes

^ai.e. doses, dates etc. for patients identified as GH-treated.

^bi.e. at the time of treatment.

^ci.e. extracted specially for SAGhE from existing case notes.